A new study will investigate the long-term safety and effects of the experimental treatment buntanetap in people with Parkinson’s disease, according to Annovis Bio, the therapy’s developer. The open-label extension (OLE) study (NCT07284784) is expected to enroll about 500 adults with Parkinson’s disease, ages 40 to 85,…
